Smell in Covid-19 and Efficacy of Nasal Theophylline
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily.
Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence
using objective olfactory testing could be even higher.
We propose a phase II single-site, double-blinded, placebo-controlled randomized clinical
trial to determine the efficacy and safety of intranasal theophylline, a known
phosphodiesterase inhibitor in the treatment of asthma, as a possible treatment for COVID-19
related OD. Theophylline has shown benefit in similar clinical trials for post-viral OD.